GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » PS Ratio

Eli Lilly and Co (Eli Lilly and Co) PS Ratio

: 19.72 (As of Today)
View and export this data going back to 1970. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eli Lilly and Co's share price is $745.95. Eli Lilly and Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $37.82. Hence, Eli Lilly and Co's PS Ratio for today is 19.72.

Warning Sign:

Eli Lilly and Co stock PS Ratio (=19.75) is close to 10-year high of 20.74

The historical rank and industry rank for Eli Lilly and Co's PS Ratio or its related term are showing as below:

LLY' s PS Ratio Range Over the Past 10 Years
Min: 2.28   Med: 5.08   Max: 20.74
Current: 19.72

During the past 13 years, Eli Lilly and Co's highest PS Ratio was 20.74. The lowest was 2.28. And the median was 5.08.

LLY's PS Ratio is ranked worse than
93.43% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs LLY: 19.72

Eli Lilly and Co's Revenue per Sharefor the three months ended in Dec. 2023 was $10.35. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $37.82.

During the past 12 months, the average Revenue per Share Growth Rate of Eli Lilly and Co was 19.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.00% per year.

During the past 13 years, Eli Lilly and Co's highest 3-Year average Revenue per Share Growth Rate was 14.30% per year. The lowest was -5.70% per year. And the median was 6.50% per year.

Back to Basics: PS Ratio


Eli Lilly and Co PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.51 6.28 8.89 11.60 15.43

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.60 11.21 14.36 15.11 15.43

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co PS Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's PS Ratio falls into.



Eli Lilly and Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Eli Lilly and Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=745.95/37.818
=19.72

Eli Lilly and Co's Share Price of today is $745.95.
Eli Lilly and Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Eli Lilly and Co  (NYSE:LLY) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Eli Lilly and Co PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017

Eli Lilly and Co (Eli Lilly and Co) Headlines